Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ATF4 | P18848 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615985 | 0.89 | NOTUM (0.78) | NOTUMMAPTF2KCNJ1RAB9A | |
| SCHEMBL4582384 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1RAB9A | |
| SCHEMBL11711879 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1RAB9A | |
| SCHEMBL8485436 | 0.78 | KCNJ1 (0.66) | NOTUMMAPTF2KCNJ1RAB9A | |
| SCHEMBL11831417 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1RAB9A | |
| SCHEMBL1163779 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1RAB9A | |
| SCHEMBL311636 | 0.78 | MAPT (1.00) | NOTUMMAPTF2KCNJ1RAB9A | |
| SCHEMBL82595 | 0.78 | MAPT (0.69) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL17993966 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1RAB9A | |
| SCHEMBL11118984 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-109153663-A | Triazolones and Tetrazolones as ROCK Inhibitors | 百时美施贵宝公司 | 2019-01-04 | — | — | CN | disclosed |
| EP-2888008-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2018-12-26 | — | — | EP | disclosed |
| CN-103958495-B | The compound of conditioning agent as GPR-119 | 理森制药股份公司 | 2018-06-22 | — | — | CN | disclosed |
| US-9868733-B2 | Azabenzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180009807-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2018-01-11 | — | — | US | disclosed |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| EP-2718279-B1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-10 | — | — | EP | disclosed |
| CN-102898400-A | GPR119 agonist and application thereof | BEIJING HANMEI PHARMACEUTICAL CO LTD | 2013-01-30 | — | — | CN | disclosed |
| WO-2012170867-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012103806-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012103806-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-08-09 | — | — | WO | disclosed |
| CN-102617548-A | Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof | BEIJING CENTAURUS BIOPHARMA TECHNOLOGY CO LTD | 2012-08-01 | — | — | CN | disclosed |
| EP-2408742-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2012-01-25 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010048149-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2006018682-A2 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | NOTUM 157/4885MAPT 1648/4885F2 2579/4885 |
| US-20180009807-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | NOTUM 4305/4885MAPT 4320/4885F2 4683/4885 |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | NOTUM 4629/4885MAPT 3977/4885F2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.